We thank Dr. Laurenzi for his thorough review and critique of our recent article “Roflumilast:
a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary
disease,” published in the January 2012 issue of Clinical Therapeutics.
1
While several of the suggested changes are minor and would not substantially alter
the findings, as stated by Dr. Laurenzi, we want to clarify and correct a few of the
highlighted items. Items 1 to 7 and 9 are accurate, with the differences likely due
to rounding (5b), attempts to provide representative data without being exhaustive
(1, 3, 4a–c, 5a, and 9), and errors made while compiling the data (2, 5c, 6, and 7);
therefore, we see no need to discuss them further in this response. Specifically,
with regard to item 12, Table III included the values for forced expiratory volume
in 1 second (FEV1) that corresponded to the stage of COPD required for inclusion to the study; however,
in the text we addressed only the minimum stage required for study inclusion.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.Clin Ther. 2012; 34: 56-66
- Daxas (roflumilast) in Chronic Obstructive Pulmonary Disease.(Accessed June 6, 2012)
- Summary Minutes of the Pulmonary-Allergy Drugs Advisory Committee, April 7, 2010.(Accessed June 6, 2012)
- The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease.Ther Adv Respir Dis. 2010; 4: 195-198
- Daliresp [package insert].Forrest Pharmaceuticals, St. Louis, MO2010
Article info
Publication history
Published online: July 06, 2012
Identification
Copyright
© 2012 Elsevier HS Journals, Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Dear Dr. WalsonClinical TherapeuticsVol. 34Issue 8
- PreviewIn the January 2012 issue of Clinical Therapeutics, we were pleased to see the article on a new treatment of chronic obstructive pulmonary disease, roflumilast, by Pinner et al,1 titled “Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.” Since roflumilast was recently approved, the review is especially timely for educating readers on this drug. In support of this, we would like the published information to be as accurate as possible. Please consider the following inaccuracies in the article:
- Full-Text
- Preview
